TB-500 (thymosin beta-4 fragment, amino acids 17–23, Ac-LKKTETQ) is a synthetic heptapeptide derived from the actin-binding domain of the endogenous protein thymosin beta-4 (Tβ4). No published human or animal pharmacokinetic study has formally established TB-500's plasma half-life[1]. Based on structural characteristics — a 7-amino-acid acetylated peptide, MW ~796 Da, no half-life extension technology — plasma clearance is estimated at minutes to low hours via proteolytic degradation. TB-500 promotes actin polymerisation, wound healing, and angiogenesis. All efficacy data derives from animal studies of the parent protein Tβ4 — no FDA approval; research use only.
| Parameter | Value | Source |
|---|---|---|
| Plasma Half-Life | Not formally established | No published PK study |
| Estimated Half-Life (inferred) | Minutes to low hours | Structural analog inference [1] |
| Time to Peak (Tmax) | No published data | — |
| Route(s) of Administration | SC injection, IM injection | — |
| Plasma Protein Binding | No published data | — |
| Full Clearance (5 × t½) | Not calculable — half-life not established | — |
| Standard Research Protocol | 2–2.5 mg SC or IM, 2× weekly | Community protocol |
| Data Quality | Animal Study — No published human or animal PK study for TB-500 fragment as of May 2026 | — |
TB-500's plasma half-life has not been formally established in any published pharmacokinetic study. This is a genuine data gap: unlike BPC-157, which has rat pharmacokinetic characterization (Xu et al. 2022, PMC9794587), TB-500 lacks published PK parameters for the isolated fragment in peer-reviewed literature as of May 2026.
Goldstein et al. (2012, PMID 22568676)[1] reviewed the biological activities of thymosin beta-4 and established that the Ac-LKKTETQ fragment (TB-500) contains the primary actin-binding domain responsible for most of Tβ4's wound healing and angiogenic effects. This foundational paper defines the mechanism of TB-500 but does not characterize pharmacokinetic parameters. Based on structural analysis — TB-500 is a 7-amino-acid acetylated peptide (MW ~796 Da) with no albumin-binding modifications, no PEGylation, and no structural stabilization — rapid proteolytic degradation and renal filtration is expected.
TB-500 and thymosin beta-4 must not be conflated in pharmacokinetic discussions. Thymosin beta-4 (full 43-amino-acid endogenous protein) has been studied in human clinical trials for wound healing, cardiac repair, and dry eye disease. The parent protein's PK in humans has been partially characterized. TB-500 is the synthetic 7-amino-acid fragment (amino acids 17–23) — a structurally and pharmacokinetically distinct molecule with different molecular weight, clearance kinetics, and tissue distribution. PK data from Tβ4 clinical trials does not directly apply to TB-500[1].
TB-500's biological effect duration is expected to substantially exceed its plasma half-life. The primary mechanism — G-actin sequestration via the Ac-LKKTETQ motif, facilitating actin polymerisation, cell migration, VEGF upregulation, and angiogenesis — involves initiation of signaling cascades that continue independently of the peptide's plasma presence. Animal studies show biological effects (wound healing, tissue repair, angiogenesis) manifesting over days to weeks — timescales entirely inconsistent with a plasma half-life of minutes[1].
Because TB-500's plasma half-life has not been formally established, a precise clearance timeline cannot be calculated. The following table is illustrative — values are theoretical and not derived from published data:
| Half-Lives Elapsed | Time Post-Injection (Estimated) | % Remaining (Theoretical) |
|---|---|---|
| 1 | Unknown — half-life not established | 50% (theoretical) |
| 2 | Unknown | 25% (theoretical) |
| 3 | Unknown | 12.5% (theoretical) |
| 4 | Unknown | 6.25% (theoretical) |
| 5 (clearance threshold) | Unknown | ~3% (theoretical) |
| Biological effect duration | Days to weeks (animal data) | — |
Based on peptide class pharmacokinetics for small unmodified heptapeptides (MW ~796 Da), systemic plasma clearance following subcutaneous injection is expected to occur within hours. However, biological effect duration — driven by G-actin sequestration, VEGF upregulation, and downstream angiogenic cascade activation — is expected to persist for 24–72+ hours based on analogy to thymosin beta-4 animal data[1].
TB-500 research protocols use 2–2.5 mg SC or IM twice weekly. This frequency is empirically derived — not pharmacokinetically optimized — because no formal PK data exists to inform protocol design. The twice-weekly interval likely reflects the timescale of biological effect replenishment (actin dynamics, wound healing signaling) rather than maintenance of plasma concentrations. The cascade-driven mechanism means plasma trough management — the standard rationale for dosing frequency in most drugs — does not apply straightforwardly to TB-500[1].
| Compound | Plasma Half-Life | Data Quality | Primary Mechanism |
|---|---|---|---|
| BPC-157 | ~15 min (SC, rat) | Animal Study | VEGFR2, Akt-eNOS signaling |
| TB-500 | Not established | Inferred — no published PK | Actin polymerisation, VEGF upregulation |
| GHK-Cu | ~0.5–1 hr (estimated) | Animal/In-vitro | TGF-β, collagen synthesis, MMP modulation |
| KPV | Minutes (estimated) | Animal/In-vitro | MC1R anti-inflammatory, NF-κB suppression |
| Route | Half-Life | Bioavailability | Tmax | Notes |
|---|---|---|---|---|
| Subcutaneous | No published data | No published data | No published data | Most common in research protocols |
| Intramuscular | No published data | No published data | No published data | Used in some research protocols |
| Intravenous | No published data | 100% | Minutes | Reference route; no published PK data |
| Oral | Not viable (estimated) | Likely very low | Unknown | Not used; peptide degradation expected |
TB-500 is not detected by standard workplace urine drug screens, standard WADA anti-doping panels in current use, or any broadly deployed drug testing platform. Standard immunoassay drug tests target specific controlled substance classes and have no cross-reactivity with peptide compounds like TB-500.
Thymosin beta-4 and related peptides have received regulatory attention from WADA. Specialized LC-MS/MS detection methods for thymosin peptides in biological fluids have been developed for research use. No published human forensic detection study has characterized the urinary detection window for the TB-500 fragment (Ac-LKKTETQ) specifically. Competitive athletes should be aware that anti-doping methodology for thymosin-class peptides continues to evolve.
TB-500's pharmacokinetic profile is uncertain not because of structural complexity, but because it is a structurally simple short peptide that predicts rapid clearance — and short-half-life peptides used in research rarely receive dedicated PK characterization in published literature. The Ac-LKKTETQ sequence is a 7-amino-acid acetylated heptapeptide (MW ~796 Da) with no albumin-binding modifications, no PEGylation, and no cyclization. Circulating serum peptidases and tissue-bound proteases rapidly cleave such sequences, and the small molecular weight enables renal glomerular filtration[1].
Despite rapid expected plasma clearance, TB-500's biological mechanism is well characterized. The Ac-LKKTETQ domain sequesters G-actin (globular actin) monomers in a 1:1 complex, reducing the G-actin pool available for spontaneous F-actin (filamentous actin) polymerisation. This regulatory effect on actin dynamics drives downstream biological responses: enhanced cell migration (critical for wound healing), VEGF-mediated angiogenesis, and tissue repair signaling cascades[1]. Goldstein et al. (2012) documented animal study evidence of TB-500/Tβ4-mediated acceleration of wound healing, cardiac repair, and corneal regeneration with effects manifesting over days to weeks — a timescale orders of magnitude longer than the expected plasma half-life, confirming substantial pharmacokinetic/pharmacodynamic dissociation.
This dissociation — rapid plasma clearance paired with prolonged biological effect — is the defining pharmacological characteristic shared by most signaling repair peptides including BPC-157, GHK-Cu, and LL-37. The peptide triggers downstream biological programs; it does not need to remain in plasma to sustain them. Understanding this principle is essential for interpreting TB-500's short expected half-life in the context of protocols that use twice-weekly dosing.
Log injection timing, dose, and site rotation on-device with no data shared externally.
Download on App StoreThe Halflife app tracks TB-500 alongside 44 other compounds — all with citation-backed pharmacokinetic data from FDA labels and published literature. Free on iOS.
Download on the App Store